MedTrace Logo

Varenicline Effects In Schizophrenic Smokers

NCT00548470 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-09-20

Study results available
· View outcomes & findings →

Summary

This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are assessed on subjective and objective measures of smoking, selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline (1-2 mg/day).

Conditions

Interventions

DRUG

Varenicline

Varenicline 1-2 mg/day

Sponsors & Collaborators

  • University of Illinois at Chicago

    collaborator OTHER

  • Nathan Kline Institute for Psychiatric Research

    lead OTHER

Principal Investigators

  • Robert C Smith, MD, PhD · Nathan Kline Institute of Psychiatric Research; NYU School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-09-30
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00548470 on ClinicalTrials.gov